Premature Labor (Tocolysis) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Premature Labor (Tocolysis) – Pipeline Review, H1 2017’, provides an overview of the Premature Labor (Tocolysis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)

– The report reviews pipeline therapeutics for Premature Labor (Tocolysis) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Premature Labor (Tocolysis) therapeutics and enlists all their major and minor projects

– The report assesses Premature Labor (Tocolysis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AMAG Pharmaceuticals Inc

GlaxoSmithKline Plc

Juniper Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Lipocine Inc

ObsEva SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Premature Labor (Tocolysis) Overview

Premature Labor (Tocolysis) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Premature Labor (Tocolysis) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Premature Labor (Tocolysis) Companies Involved in Therapeutics Development

AMAG Pharmaceuticals Inc

GlaxoSmithKline Plc

Juniper Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Lipocine Inc

ObsEva SA

Premature Labor (Tocolysis) Drug Profiles

bedoradrine sulfate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxyprogesterone caproate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxyprogesterone caproate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OBE-022 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

progesterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

retosiban Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Acute Inflammation and Premature Labor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Progesterone Receptor for Preterm Birth Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Premature Labor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Premature Labor (Tocolysis) Dormant Projects

Premature Labor (Tocolysis) Discontinued Products

Premature Labor (Tocolysis) Product Development Milestones

Featured News & Press Releases

Feb 02, 2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration

Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor

Jan 09, 2017: Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth

Oct 12, 2016: AMAG Pharmaceuticals Announces Achievement of Key Milestone in Next Generation Development Program for Makena

Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor

Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)

Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)

Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women

Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301

Nov 23, 2015: AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena

Nov 18, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena (hydroxyprogesterone caproate injection)

Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor

May 28, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena

May 20, 2015: AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth

Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Premature Labor (Tocolysis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Premature Labor (Tocolysis) Pipeline by AMAG Pharmaceuticals Inc, H1 2017

Premature Labor (Tocolysis) Pipeline by GlaxoSmithKline Plc, H1 2017

Premature Labor (Tocolysis) Pipeline by Juniper Pharmaceuticals Inc, H1 2017

Premature Labor (Tocolysis) Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Premature Labor (Tocolysis) Pipeline by Lipocine Inc, H1 2017

Premature Labor (Tocolysis) Pipeline by ObsEva SA, H1 2017

Premature Labor (Tocolysis) Dormant Projects, H1 2017

Premature Labor (Tocolysis) Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Premature Labor (Tocolysis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports